HER4 remains controversial because both cancer-promoting and cancer-suppressing effects have been found.41,42 Therefore, substantial efforts are being made to develop mainstream targeted drugs for HER1 and HER2 while facing potential drug resistance caused by mutations of HER1 and HER2. This evidence concerns the gene ERBB4 and cancer.